Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.
|
| Abstract |
There are two figures and one table in this review, the review consists of 5823 words, without the description of figures and table, but including references. Tumor cells escape anti-tumor immune responses in various ways, including functionally shaping the microenvironment through the secretion of various chemokines and, cytokines. Adenosine is a powerful immunosuppressive metabolite, that is frequently elevated in the extracellular tumor microenvironment (TME). Thus, it has recently been proposed as a novel antitumor immunoassay for targeting adenosine- generating enzymes, such as CD39, CD73, and adenosine receptors. In recent years, the discovery of the immune checkpoints, such as programmed cell death 1(PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), has also greatly changed treatment methods and ideas for malignant tumors. Malignant tumor immunotherapy has been developed from point-to-point therapy targeting immune checkpoints, combining different points of different pathways to create a therapy based on the macroscopic immune regulatory system network. This article reviews the theoretical basis of the adenosine energy axis and immune checkpoint combined therapy for malignant tumors and the latest advances in malignant tumors.
|
|---|---|
| Authors | Zhaoyun Liu, Xiaohan Liu, Hongli Shen, Xintong Xu, Xianghong Zhao, Rong Fu |
| Journal | Frontiers in immunology (Front Immunol) Vol. 13 Pg. 978377 ( 2022) ISSN: 1664-3224 [Electronic] Switzerland |
| PMID | 36159861 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't) |
| Copyright | Copyright © 2022 Liu, Liu, Shen, Xu, Zhao and Fu. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!